Brookstone Capital Management’s iShares Biotechnology ETF IBB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.17M | Buy |
16,689
+10,240
| +159% | +$1.76M | 0.03% | 401 |
|
|
2026
Q1 | $1.09M | Sell |
6,449
-5,586
| -46% | -$955K | 0.01% | 616 |
|
|
2025
Q4 | $2.03M | Buy |
12,035
+5,735
| +91% | +$931K | 0.02% | 451 |
|
|
2025
Q3 | $910K | Sell |
6,300
-8,520
| -57% | -$1.16M | 0.01% | 636 |
|
|
2025
Q2 | $1.87M | Buy |
14,820
+6,774
| +84% | +$832K | 0.02% | 432 |
|
|
2025
Q1 | $1.03M | Buy |
8,046
+12
| +0.1% | +$1.63K | 0.01% | 547 |
|
|
2024
Q4 | $1.06M | Sell |
8,034
-973
| -11% | -$137K | 0.02% | 515 |
|
|
2024
Q3 | $1.31M | Sell |
9,007
-11,110
| -55% | -$1.61M | 0.02% | 450 |
|
|
2024
Q2 | $2.94M | Buy |
20,117
+13,488
| +203% | +$1.8M | 0.05% | 310 |
|
|
2024
Q1 | $910K | Sell |
6,629
-124
| -2% | -$16.9K | 0.02% | 510 |
|
|
2023
Q4 | $917K | Buy |
6,753
+269
| +4% | +$32.8K | 0.02% | 479 |
|
|
2023
Q3 | $763K | Buy |
6,484
+3,925
| +153% | +$499K | 0.02% | 485 |
|
|
2023
Q2 | $318K | Buy |
2,559
+576
| +29% | +$74.8K | 0.01% | 674 |
|
|
2023
Q1 | $265K | Sell |
1,983
-6,382
| -76% | -$835K | 0.01% | 719 |
|
|
2022
Q4 | $1.11M | Sell |
8,365
-600
| -7% | -$77.5K | 0.02% | 410 |
|
|
2022
Q3 | $1.07M | Buy |
8,965
+6,982
| +352% | +$867K | 0.02% | 385 |
|
|
2022
Q2 | $251K | Sell |
1,983
-1,268
| -39% | -$151K | 0.01% | 684 |
|
|
2022
Q1 | $423K | Buy |
3,251
+751
| +30% | +$97.8K | 0.01% | 588 |
|
|
2021
Q4 | $351K | Sell |
2,500
-1,893
| -43% | -$293K | 0.01% | 593 |
|
|
2021
Q3 | $684K | Sell |
4,393
-1,088
| -20% | -$183K | 0.01% | 446 |
|
|
2021
Q2 | $882K | Buy |
5,481
+1,696
| +45% | +$261K | 0.02% | 389 |
|
|
2021
Q1 | $570K | Buy |
3,785
+1,217
| +47% | +$193K | 0.02% | 336 |
|
|
2020
Q4 | $389K | Buy |
2,568
+488
| +23% | +$69.7K | 0.02% | 353 |
|
|
2020
Q3 | $282K | Sell |
2,080
-2,012
| -49% | -$273K | 0.01% | 349 |
|
|
2020
Q2 | $559K | Buy |
+4,092
| New | +$522K | 0.03% | 222 |
|
|
2019
Q2 | – | Sell |
-1,984
| Closed | -$222K | – | 457 |
|
|
2019
Q1 | $222K | Buy |
+1,984
| New | +$218K | 0.01% | 363 |
|
|
2016
Q4 | – | Sell |
-5,907
| Closed | -$570K | – | 249 |
|
|
2016
Q3 | $570K | Buy |
+5,907
| New | +$562K | 0.06% | 165 |
|
|
2015
Q4 | – | Sell |
-24,399
| Closed | -$2.47M | – | 480 |
|
|
2015
Q3 | $2.47M | Buy |
24,399
+5,679
| +30% | +$681K | 0.45% | 27 |
|
|
2015
Q2 | $2.3M | Buy |
+18,720
| New | +$2.24M | 0.29% | 82 |
|
Other funds holding IBB
CB
Brookstone Capital Management's IBB Position: Q2 2026 in Review
Brookstone Capital Management increased its iShares Biotechnology ETF (IBB) stake by 159% in Q2 2026, buying an estimated $1.76M and bringing the position to 16,689 shares worth $3.17M. The position accounts for 0.03% of the portfolio, ranked #401.
Brookstone Capital Management first reported a position in IBB in Q2 2015 and has held it in 29 quarters since. 954 funds tracked by Wall St. Rank hold IBB as of Q2 2026.
- Brookstone Capital Management held 16,689 shares of iShares Biotechnology ETF worth $3.17M as of Q2 2026.
- Brookstone Capital Management bought 10,240 iShares Biotechnology ETF shares in Q2 2026, an estimated $1.76M.
- iShares Biotechnology ETF made up 0.03% of Brookstone Capital Management's portfolio in Q2 2026, its #401 holding.
- Brookstone Capital Management first reported a position in iShares Biotechnology ETF in Q2 2015 and has held it in 29 quarters since.
- 954 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.
Based on Brookstone Capital Management's 13F filing for Q2 2026, filed 15 Jul 2026.